Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Parker

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
European Urology|March 21, 2017
Low-risk Prostate Cancer: Identification, Management, and OutcomesMarco Moschini, Peter R Carroll, Scott E Eggener, et al.
Advances in Therapy|March 22, 2023
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United StatesChristopher Parker, Fei Fei Liu, Kristen A Deger, et al.
JAMA Oncology|October 17, 2018
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review, Christopher Parker, Valerie Lewington, et al.
The American Journal of Emergency Medicine|September 22, 2023
Comparison of dynamic versus static ultrasound to confirm endotracheal tube depthMichael Gottlieb, Nicholas Cozzi, Molly Hartrich, et al.
The Prostate|March 24, 2016
Chemotherapy following radium-223 dichloride treatment in ALSYMPCAOliver Sartor, Peter Hoskin, Robert E Coleman, et al.
Journal of Medical Economics|July 30, 2016
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in ScotlandChristopher Parker, Beth Woods, James Eaton, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
European Urology Focus|February 4, 2016
The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An UpdateAhmed El-Shater Bosaily, Christopher Parker, Louise C Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2016
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trialChristopher Parker, Lin Zhan, Paul Cislo, et al.
The Medical Journal of Australia|October 22, 2014
Hepatocellular carcinoma in Australia's Northern Territory: high incidence and poor outcomeChristopher Parker, Steven Y C Tong, Karen Dempsey, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
European Urology|March 21, 2017
Low-risk Prostate Cancer: Identification, Management, and OutcomesMarco Moschini, Peter R Carroll, Scott E Eggener, et al.
Advances in Therapy|March 22, 2023
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United StatesChristopher Parker, Fei Fei Liu, Kristen A Deger, et al.
JAMA Oncology|October 17, 2018
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review, Christopher Parker, Valerie Lewington, et al.
The American Journal of Emergency Medicine|September 22, 2023
Comparison of dynamic versus static ultrasound to confirm endotracheal tube depthMichael Gottlieb, Nicholas Cozzi, Molly Hartrich, et al.
The Prostate|March 24, 2016
Chemotherapy following radium-223 dichloride treatment in ALSYMPCAOliver Sartor, Peter Hoskin, Robert E Coleman, et al.
Journal of Medical Economics|July 30, 2016
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in ScotlandChristopher Parker, Beth Woods, James Eaton, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
European Urology Focus|February 4, 2016
The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An UpdateAhmed El-Shater Bosaily, Christopher Parker, Louise C Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2016
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trialChristopher Parker, Lin Zhan, Paul Cislo, et al.
The Medical Journal of Australia|October 22, 2014
Hepatocellular carcinoma in Australia's Northern Territory: high incidence and poor outcomeChristopher Parker, Steven Y C Tong, Karen Dempsey, et al.
Pageof 8